{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-24-000032","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.203543+00:00","generated_at":"2026-06-06T01:02:40.177604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agios Q4 net loss $95.9M; positive mitapivat Phase 3 for NTD thalassemia","bullets":["Q4 PYRUKYND US net revenue $7.1M (down 4% QoQ); full year 2023 $26.8M.","Net loss $95.9M in Q4 vs net income $36.5M in Q4 2022; full year loss $352.1M.","Positive Phase 3 ENERGIZE study in non-transfusion-dependent thalassemia met primary endpoint.","Cash & equivalents $806.4M; company expects runway into 2026.","Pipeline milestones: ENERGIZE-T data mid-2024; FDA filing for mitapivat in thalassemia end-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-24-000032","json":"https://secwatch.observer/filing/0001439222-24-000032.json","markdown":"https://secwatch.observer/filing/0001439222-24-000032.md","text":"https://secwatch.observer/filing/0001439222-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000032/0001439222-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000032/agio-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:02:40.177604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49757b61742f284bd684fd58e3466fdb17d2b83a","claim":"AGIOS PHARMACEUTICALS, INC. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On February 15, 2024, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2023 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000032/0001439222-24-000032-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}